Tmem178 negatively regulates IL-1β production through inhibition of the NLRP3 inflammasome.
Kunjan KhannaHui YanMuneshwar MehraNidhi RohatgiGabriel MbalavieleElizabeth D MellinsRoberta FaccioPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Downregulation of TMEM178 levels may represent a marker of disease activity and help identify patients that could benefit from inflammasome targeting.
Keyphrases
- disease activity
- nlrp inflammasome
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- newly diagnosed
- ejection fraction
- ankylosing spondylitis
- chronic kidney disease
- cell proliferation
- prognostic factors
- juvenile idiopathic arthritis
- peritoneal dialysis
- signaling pathway
- drug delivery
- patient reported outcomes